- Home
- GDL vs CLNN Comparison
GDL vs CLNN Comparison
Compare GDL & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GDL | CLNN |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | United States | United States |
| Employees | N/A | 79 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.7M | 85.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GDL | CLNN |
|---|---|---|
| Price | $8.42 | $5.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $33.75 |
| AVG Volume (30 Days) | 8.9K | ★ 141.8K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 6.02% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $17.64 |
| Revenue Next Year | N/A | $19,516.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.20 | $3.25 |
| 52 Week High | $8.67 | $13.50 |
Technical Indicators
Market Signals| Indicator | GDL | CLNN |
|---|---|---|
| Relative Strength Index (RSI) | 42.67 | 40.22 |
| Support Level | $8.39 | $4.48 |
| Resistance Level | $8.53 | $6.92 |
| Average True Range (ATR) | 0.06 | 0.40 |
| MACD | -0.01 | -0.16 |
| Stochastic Oscillator | 7.62 | 18.45 |
Price Performance
Historical ComparisonAbout GDL GDL Fund The of Beneficial Interest
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.